Utah Medical Products (UTMD) reported third-quarter 2026 revenue of $8,621 thousand, down 12.1% from $9,812 thousand a year earlier, and nine-month revenue fell $3,602 thousand (12.1%). The drop mainly reflects no 2026 sales to former top customers PendoTECH and a China BPM kit distributor, plus a 32.7% fall in Filshie Clip System sales, partly offset by new biopharm sales and the Orion Medical Supplies acquisition. Gross profit fell $764 thousand in the quarter, but operating income improved as litigation and amortization expenses dropped to $228 thousand from $920 thousand, and net income rose about 6%. The company stayed debt-free, with cash and investments of $85.2 million at September 30, 2026, versus $85.8 million at year-end 2025, after dividends, buybacks and the $5.0 million Orion purchase.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on tennesseedaily.com ↗
Keywords
Utah Medical Productsearningshealthcaremedical devices
Open a keyword to see other news on the same topic.
Related news
- Integra (IART) Q3 2026 Earnings Call Transcript
Integra (IART) reported Q3 revenue of $411.2 million, up 2.5% organically despite a $7 million hit from flooding at its Cincinnati facility, with adjusted EPS of $0.59 versus $0.54 a year earlier. Specialty Surgery revenue rose 4.2% to $304.1 million, led by neurosurgery (up 6.5%) and international markets (up 7.8%), while Tissue Reconstruction fell 2.2% to $107.1 million on competitive pressure in its urinary bladder matrix (UBM) portfolio. Management expects a further $15–20 million revenue reduction in Q4 and lowered full-year 2026 revenue guidance to $1.634–1.654 billion, with adjusted EPS guidance of $2.30–2.40. The $2.1 billion debt refinancing completed October 19, 2026 is expected to add about $8 million in interest expense in Q4 and $24 million in 2027, though net debt remained $1.5 billion with a 3.8x leverage ratio.
- Johnson & Johnson Introduce Coronary IVL Catheter
Johnson & Johnson has launched the Shockwave C2 Aero Fly Coronary IVL catheter in the U.S., designed to treat calcified coronary artery lesions in half the time of previous coronary IVL devices. The catheter delivers pulses at double the speed and cuts pause time between cycles to five seconds, reducing treatment time from 230 seconds to 115 seconds and lowering patients’ ischemic time. Coronary artery disease is the leading cause of death globally, affecting an estimated 315 million people worldwide. The device will be showcased at TCT 2026 in San Diego, California, from October 31 to November 3, 2026.
- FDA Alert Follows Death Linked to Edwards Device - Orange County Business Journal
The FDA last week issued a safety notice for certain delivery systems used in Edwards Lifesciences' Sapien M3 transcatheter mitral valve replacement, after three balloon bursts occurred during inflation. As of Oct. 5, Edwards reported three incidents, including one death and one serious injury. The company told customers to stop using and return devices from four lot numbers of its Commander M delivery systems. Since the Oct. 15 alert, Edwards shares (EW) have fallen 1.3% to $86.94, with a market cap of about $50 billion.
- Philip Morris International Reports 2026 Third-Quarter & First Nine-Months Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only
Philip Morris International reported third-quarter 2026 reported diluted EPS of $2.12, down 4.9% mainly due to a non-cash fair value adjustment on equity investments, while adjusted diluted EPS rose 5.4% to $2.36. Net revenues grew 5.5% (7.1% organically) to $11.4 billion, a quarterly record, with operating income up 14.1% and smoke-free products making up more than 40% of revenue. Shipments rose 0.6%, supported by a 2.7% increase in smoke-free products, with IQOS heat-not-burn shipments up 1.5% to 41.5 billion units. Oral smoke-free volumes turned positive, rising 0.5%, as modern oral grew 20.6%, and VEEV e-vapor shipments jumped 61.6%.
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx reported third-quarter 2026 global product net sales of VYVGART of $1.7 billion, up 54% year over year and 13% quarter over quarter. Positive Phase 3 ALKIVIA results showed consistent treatment effects in IMNM and dermatomyositis, with an sBLA for IMNM on track for submission by year-end 2026. The company submitted an sBLA for ocular myasthenia gravis to the FDA, and a pediatric gMG sBLA was accepted for priority review with a PDUFA target date in February 2027. Phase 3 EMPASSION topline results for empasiprubart in MMN are expected in December 2026, while FB102 is advancing to Phase 3 in celiac disease. argenx continues to target treating 50,000 patients, securing 10 labeled indications and advancing five candidates into registrational development by 2030.
- Kinder Morgan Reports Record Third Quarter 2026 Financial Results
Kinder Morgan declared a third-quarter cash dividend of $0.2975 per share ($1.19 annualized), payable November 16, 2026, a 2% increase over the third quarter of 2025. The company reported net income attributable to KMI of $764 million, up from $628 million a year earlier, and Adjusted EBITDA of $2.18 billion, up 9%. EPS and Adjusted EPS were $0.34 and $0.35, both up 21% year over year. Its expansion project backlog rose $4.7 billion from the second quarter to $14.4 billion, including a record $13.2 billion natural gas portion that adds the Southeast Connector and Permian Link pipeline projects. Net debt to Adjusted EBITDA was 3.5 times, at the low end of its target range.
Related markets
Latest news
- Musk's wants to merge SpaceX and Tesla: Here's what to know
Musk said SpaceX and Tesla have formed special committees to study a merger, which would be worth about $3.5 trillion combined and would be the largest corporate deal in history. SpaceX, valued at about $2 trillion after a record listing this year, absorbed Musk's AI startup xAI in February, while Tesla is valued at about $1.5 trillion. Musk holds about 82 percent of SpaceX's voting power but only about 20 percent at Tesla. Dan Ives puts the odds of a deal at 90 percent by early 2027, though Musk called the requirement of a majority of all Tesla shares 'quite a high hurdle'. Loyal retail investors hold an estimated 25 to 27 percent of Tesla shares, and legal obstacles appear slight because both companies moved their incorporation to Texas from Delaware.
- CoreWeave and Nebius Stocks Are Crashing. Time to Buy the Dip?
Shares of Nebius and CoreWeave each fell 25% in the week of October 12 to 16. The sell-off stems from the yield on CoreWeave's debt in the secondary market surging to 15%, versus roughly 5% on Treasuries, which pushes the debt into 'distressed' territory and signals doubts about its ability to meet obligations. Nebius sold off in sympathy as a fellow neocloud company. The bigger concern is that both companies must keep issuing debt to fund data centers, and if yields are high at issuance, the assumption of nearly unlimited cheap capital could be challenged. The author says it is unclear whether now is the time to buy.
- Disney’s multiplatform Super Bowl plan frustrates ABC affiliates
ABC station owners are irritated that Disney is airing the Super Bowl across several platforms, including Disney+, ESPN2, NFL Network and ESPNU, even though the game is already on ABC and ESPN. A station group CEO estimates that the combined platforms could cut broadcast ad revenue by up to 35% compared with last year. Local affiliates typically earn about 3% of annual ad revenue from the Super Bowl and pay network owners reverse retransmission fees, but Disney+ lacks geofenced ad insertion, so affiliates cannot sell ads to streaming viewers. Disney says national commercials will be identical on all platforms and that streaming major live events is standard industry practice. Super Bowl LX drew 125.6 million viewers in February.
- Nasdaq sell-off: A momentum unwind 'for the record books'
Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management, calls Thursday’s sell-off in the Nasdaq Composite (^IXIC) a momentum unwind “for the record books.” He says the market spent the first half of 2026 driven by a beta and momentum trade led by semiconductors, but in the third quarter, as rates rose, money shifted into quality stocks. He does not think the sell-off is justified by fundamentals, arguing that institutional portfolio managers swapping out of factor positions can drag down whole baskets of stocks. In semiconductors, spot rental rates for Nvidia Blackwell chips are higher than a month ago, showing tightening compute supply, even as financing costs rise and investors worry about neocloud business models and the rising cost of insuring their bonds.
- Meta’s deal to keep Zuckerberg in California adds fuel to wealth tax debate ahead of election
Meta says Mark Zuckerberg will remain in California for eight years and has created a new stock plan that could help cover his taxes if Proposition 40, a 5% tax on Californians worth over $1 billion, passes on Election Day on Nov. 3. According to a filing released with its third-quarter earnings, Meta will issue non-voting Class C shares starting in January, and Zuckerberg can sell or transfer up to 20% of the shares granted to him without affecting his majority voting control. The filing says Zuckerberg’s leadership is crucial to the company’s growth and its AI ambitions, including Meta Superintelligence Labs. Most of the tech industry opposes the measure, while a recent Citrin-Politico poll found 46% in favor and 43% against, suggesting it may fall short of the majority support it needs.
- Dune launches real-time data feeds covering 200 onchain trading venues
Blockchain analytics platform Dune has launched real-time market data feeds covering more than 200 onchain trading venues, aiming to bring this data into the systems of traditional financial institutions. The feeds draw trade data from 12 blockchains, including Ethereum, Solana and Base, about one second after execution, covering both spot trading on decentralized exchanges and perpetual futures on Hyperliquid and Lighter. Early clients include quant funds, market makers, asset managers and bank trading desks, which use the data to assess liquidity and compare prices, though Dune did not name them. Meanwhile, the tokenized stock market has grown sharply, with distributed value reaching $3.58 billion, but 16 companies, including Microsoft, Alphabet and Goldman Sachs, have objected to their shares being traded on OKXICE’s proposed platform, and liquidity remains fragmented.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.